{"id":"W1940434397","doi":"10.1007/s00280-015-2852-2","title":"Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"Georgetown Hospital","funders":"Lombardi Comprehensive Cancer Center, Georgetown University; American Cancer Society","keywords":"Medicine; Sorafenib; Tolerability; Internal medicine; Clinical endpoint; Nausea; Hepatocellular carcinoma; Temozolomide; Phases of clinical research; Regimen; Veliparib; Gastroenterology; Surgery; Progressive disease; Vomiting; Oncology; Clinical trial; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002145994,0.0002242827,0.0005034352,0.0001047073,0.0001125755,0.000006654562,0.00005865648,0.0001162184,0.00008890665],"category_scores_gemma":[0.000007250097,0.0001937412,0.00006082955,0.0001172888,0.0001155726,0.00008708504,0.00002170581,0.000114879,4.012411e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006772835,"about_ca_system_score_gemma":0.0001467094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008129532,"about_ca_topic_score_gemma":0.000004221261,"domain_scores_codex":[0.99893,0.00007887145,0.0002864153,0.0003484104,0.0001262388,0.0002300009],"domain_scores_gemma":[0.9992411,0.00007905685,0.000152831,0.0001306792,0.0001910482,0.0002053116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0191722,0.008531049,0.4555232,0.0001690349,0.0006889927,0.00003174739,0.008122237,9.719433e-7,0.3275146,0.00002551269,0.001280718,0.1789397],"study_design_scores_gemma":[0.2407892,0.06879871,0.006780192,0.000032948,0.0006967608,0.00002349233,0.001111417,0.006547794,0.6336796,0.0002162361,0.04088556,0.000438074],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836072,0.0125481,0.00003934135,0.0008732153,0.0002672371,0.002559231,0.000025241,0.00003284173,0.00004763727],"genre_scores_gemma":[0.9957257,0.002320817,0.0001483714,0.0007539113,0.0001504468,0.0006376281,0.00003915189,0.00003598973,0.000187997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.448743,"threshold_uncertainty_score":0.7900535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09353586075040868,"score_gpt":0.3560939212492875,"score_spread":0.2625580604988789,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}